The Role of Late INa and Antiarrhythmic Drugs in EAD Formation and Termination in Purkinje Fibers
Authors:
- 21 April 2006
- journal article
- review article
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 17 (s1) , S71-S78
Abstract
Multiple components of cardiac Na current play a role in determining electrical excitation in the heart. Recently, the role of nonequilibrium components in controlling cardiac action potential plateau duration, and their importance in regulating the occurrence of afterdepolarizations and arrhythmias have garnered more attention. In particular, late Na current (late INa) has been shown to be important in LQT2 and LQT3 arrhythmias. Class III agents like dofetilide, clofilium, and sotalol, which can all cause a drug‐induced form of LQT2, significantly lengthen action potential duration at 50% and 90% repolarization in isolated rabbit Purkinje fibers, and can initiate the formation of early afterdepolarizations, and extra beats. These actions can lead to the development of a serious ventricular tachycardia, torsades de pointes, in animal models and patients. However, pretreatment with agents that block late INa, like lidocaine, mexiletine, and RSD1235, a novel mixed ion channel blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX‐II, a specific toxin that delays Na channel inactivation and amplifies late INa greatly, mimicking LQT3. The Na channel block caused by lidocaine and RSD1235 can be through the open or inactivated states of the channel, but both equivalently inhibit a late component of Na current (INa), recorded at 22°C using whole‐cell patch clamp of Nav1.5 expressed in HEK cells. These protective actions of lidocaine, mexiletine, and RSD1235 may result, at least in part, from their ability to inhibit late INa during action potential repolarization, and inhibition of the inward currents contributing to EAD and arrhythmia formation.Keywords
This publication has 49 references indexed in Scilit:
- The Mechanism of Atrial Antiarrhythmic Action of RSD1235Journal of Cardiovascular Electrophysiology, 2005
- A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillationJACC, 2004
- Oral class III antiarrhythmics: what is new?Current Opinion in Cardiology, 2004
- Assessing predictors of drug-induced torsade de pointesTrends in Pharmacological Sciences, 2003
- Cytosolic Ca2+ triggers early afterdepolarizations and torsade de pointes in rabbit hearts with type 2 long QT syndromeThe Journal of Physiology, 2002
- Differences in action potential and early afterdepolarization properties in LQT2 and LQT3 models of long QT syndromeBritish Journal of Pharmacology, 2001
- The M Cell:Journal of Cardiovascular Electrophysiology, 1999
- Mechanisms of atrial fibrillation and action of drugs used in its managementThe American Journal of Cardiology, 1998
- Electrophysiological and inotropic effects of H 234/09 (almokalant) in vitro: a comparison with two other novel IK blocking drugs, UK-68,798 (dofetilide) and E-4031Cardiovascular Research, 1993
- Mexiletine-quinidine combination: Electrophysiologic correlates of a favorable antiarrhythmic interaction in humansJACC, 1987